Search

Your search keyword '"Concin, Nicole"' showing total 534 results
Start Over Author "Concin, Nicole"
534 results on '"Concin, Nicole"'

153. Clinical characterization of long term survivors (LTS) in ovarian cancer (OC): Results of a propensity score matched (PSM) analysis of the international prospective tumor bank for ovarian cancer (TOC Network).

Author

Braicu, Elena Ioana, primary, Woopen, Hannah, additional, Glajzer, Joanna, additional, Hunsicker, Oliver, additional, Woelber, Linn, additional, Feldheiser, Aarne, additional, van Nieuwenhuysen, Els, additional, Mueller, Michael D, additional, Concin, Nicole, additional, Achimas, Patrick, additional, Ruscito, Ilary, additional, Mahner, Sven, additional, Benedetti Panici, Pierluigi, additional, Gasparri, Maria Luisa, additional, Papadia, Andrea, additional, Birrer, Michael J., additional, Vergote, Ignace, additional, Darb-Esfahani, Silvia, additional, and Sehouli, Jalid, additional

Published
2017
Full Text
View/download PDF

154. Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice

Author

Leroy, Bernard, primary, Ballinger, Mandy L., additional, Baran-Marszak, Fanny, additional, Bond, Gareth L., additional, Braithwaite, Antony, additional, Concin, Nicole, additional, Donehower, Lawrence A., additional, El-Deiry, Wafik S., additional, Fenaux, Pierre, additional, Gaidano, Gianluca, additional, Langerød, Anita, additional, Hellstrom-Lindberg, Eva, additional, Iggo, Richard, additional, Lehmann-Che, Jacqueline, additional, Mai, Phuong L., additional, Malkin, David, additional, Moll, Ute M., additional, Myers, Jeffrey N., additional, Nichols, Kim E., additional, Pospisilova, Sarka, additional, Ashton-Prolla, Patricia, additional, Rossi, Davide, additional, Savage, Sharon A., additional, Strong, Louise C., additional, Tonin, Patricia N., additional, Zeillinger, Robert, additional, Zenz, Thorsten, additional, Fraumeni, Joseph F., additional, Taschner, Peter E.M., additional, Hainaut, Pierre, additional, and Soussi, Thierry, additional

Published
2017
Full Text
View/download PDF

156. L1CAM in the Early Enteric and Urogenital System

Author

Pechriggl, Elisabeth Judith, primary, Concin, Nicole, additional, Blumer, Michael J., additional, Bitsche, Mario, additional, Zwierzina, Marit, additional, Dudas, Jozsef, additional, Koziel, Katarzyna, additional, Altevogt, Peter, additional, Zeimet, Alain-Gustave, additional, and Fritsch, Helga, additional

Published
2016
Full Text
View/download PDF

158. Clonal Hematopoiesis in Whole-Blood and Cell-Free DNA of Ovarian Cancer Patients Undergoing PARP-Inhibitor Treatment: An Exploratory Analysis of the ENGOT-ov48/Eudario Trial

Author

Arends, Christopher Maximilian, Kopp, Klara, Estrada-Barreras, Natalia, Hablesreiter, Raphael, Concin, Nicole, Moll, Ute, Zeilinger, Robert, Schmitt, Wolfgang, Sehouli, Jalid, Kulbe, Hagen, Ray-Coquard, Isabelle, Zeimet, Alain, Raspagliesi, Francesco, Zamagni, Claudio, Vergote, Ignace, Lorusso, Domenica, Bullinger, Lars, Braicu, Elena Ioana, and Damm, Frederik

Abstract

Clonal hematopoiesis (CH), characterized by the expansion of somatically mutated hematopoietic stem cells, is an age-related phenomenon associated with the development of hematologic malignancies, increased cardiovascular risk, and other age-related proinflammatory conditions. In patients with solid tumors, cytotoxic therapies differentially select for clones with mutations in the DNA damage response (DDR) pathway, i.e. TP53and PPM1D, leading to an elevated risk for therapy-related myeloid malignancies (t-MNs). Poly(ADP-ribose) polymerase inhibitors (PARPi) are frequently used to treat ovarian cancer with particularly high efficacy reported in tumors exhibiting homologous recombination (HR) deficiency caused by mutations in BRCA1/2or other HR pathway genes. However, recent data indicate that PARPi treatment is also associated with an elevated risk for t-MNs.

Published
2023
Full Text
View/download PDF

160. Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer

Author

Schmid, Gabriel, primary, Notaro, Sara, additional, Reimer, Daniel, additional, Abdel-Azim, Samira, additional, Duggan-Peer, Michaela, additional, Holly, Jessica, additional, Fiegl, Heidi, additional, Rössler, Julia, additional, Wiedemair, Annemarie, additional, Concin, Nicole, additional, Altevogt, Peter, additional, Marth, Christian, additional, and Zeimet, Alain Gustave, additional

Published
2016
Full Text
View/download PDF

163. The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients—results from the OVCAD study

Author

Nassir, Mani, primary, Guan, Jun, additional, Luketina, Hrvoje, additional, Siepmann, Timo, additional, Rohr, Irena, additional, Richter, Rolf, additional, Castillo-Tong, Dan Cacsire, additional, Zeillinger, Robert, additional, Vergote, Ignace, additional, Van Nieuwenhuysen, Els, additional, Concin, Nicole, additional, Marth, Christian, additional, Hall, Christina, additional, Mahner, Sven, additional, Woelber, Linn, additional, Sehouli, Jalid, additional, and Braicu, Elena Ioana, additional

Published
2015
Full Text
View/download PDF

164. Part I of GANNET53: A multicenter phase I/II trial of the Hsp90 inhibitor ganetespib (G) combined with weekly paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.

Author

Ray-Coquard, Isabelle, primary, Braicu, Ioana, additional, Berger, Regina, additional, Mahner, Sven, additional, Sehouli, Jalid, additional, Zeimet, Alain G, additional, Pujade Lauraine, Eric, additional, Cassier, Philippe Alexandre, additional, Moll, Utemartha, additional, Ulmer, Hanno, additional, Leunen, Karin, additional, Marth, Christian, additional, Vergote, Ignace, additional, and Concin, Nicole, additional

Published
2015
Full Text
View/download PDF

167. The clinical revalence of p53 isoforms in ovarian cancer

Author

Hofstetter, Gerda, Concin, Nicole, Berger, Astrid, Fiegl, Heidi, Slade, Neda, Zorić, Arijana, Tong, D, Holzer, Barbara, Schuster, E., Wolf, Andrea, Marth, Christian, Zeimet, Alain, and Zeillinger, Robert

Subjects
p53 splicing variant, p73, ovarian carcinoma
Abstract

p53 splice variants were present in 18 of 34 ovarian cancer cell lines (52.9%) and 134 of 245 primary ovarian cancers (54.7%). p53delta expression was associated with impaired response to primary platinum-based chemotherapy (P=0.032). Also, p53delta expression constituted an independent prognostic marker for recurrence-free and overall survival (hazard ratio 1.854, 95% confidence interval 1.121–3.065, P=0.016 ; and hazard ratio 1.937, 95% confidence interval 1.177–3.186, P=0.009, respectively). p53beta expression was associated with adverse clinicopathologic markers, that is, serous and poorly differentiated cancers (P=0.002 and P=0.008, respectively), and correlated with worse recurrence-free survival in patients exhibiting functionally active p53 (P=0.049).

Published
2010

168. The effect of p53 isoforms/splice variants on p73 activity

Author

Slade, Neda, Zorić, Arijana, Horvat, Anđela, Hofstetter, Gerda, Berger, Astrid, Concin, Nicole, Zeillinger, Robert, Kovarik, Zrinka, and Varljen, Jadranka

Subjects
p53 isoforms, splice variants, p73
Abstract

TP53 tumor suppressor protein is crucial in the cell growth control and the maintenance of genomic stability. These activities are due, at least in part, to its ability to form tetramers that bind to specific DNA sequences and activate transcription. The homologues of p53, proteins p63 and p73, can transcriptionally activate p53 target genes in vivo. Both p63 and p73 generate transactivating forms (TAp73/TAp63) as well as a number of N-terminally truncated transactivation-deficient transdominant isoforms (called ΔTAp73/ΔTAp63). It was recently discovered that p53, like p73, has a second promoter P2 and undergoes alternative splicing to generate multiple isoforms that might play important roles in carcinogenesis. Since some mutant p53 form complexes with TAp73α or TAp73β it was important to find out whether p53 isoforms can do the same and potentially act as dominant-negative inhibitors of TAp73 and TAp63. All six p53 isoforms can form complex with TAp73β, while only isoforms D133p53, D133p53β and D133p53γ can form complex with TAp73α. Inhibitory interactions of two proteins in complex often lead to their stabilization. Our results have shown that only three isoforms (Δ133p53, Δ133p53β and Δ40p53) stabilize TAp73β. Furthermore, we have shown that all isoforms of p53 inhibit transcriptional activity but with different efficiency. The apoptotic acitivity of TAp73β was augmented by coexpression of p53, but Δ133p53 and Δ133p53β inhibit its apoptotic activity most efficiently. The half lives of different p53 isoforms were determined - p53γ isoform has the shortest, while Δ133p53γ has the longest half life. We have found additional p53 splice variants (p53ζ, p53δ and p53ε) arising from alternative splicing of exon 6 and intron 9, respectively, present in 52.9% ovarian cancer cell lines and in 54, 7% primary ovarian cancers. The interaction between these p53 variants and p73 has to be determined. Defining the interactions between p53/p73 would gain insight into how the p53 isoforms modulate the functions of p73. The discovery of p53/p73 network could have a major clinical impact in prognostic use and p53 targeted drug design.

Published
2010

169. HIF1α is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer – a study of the OVCAD Consortium

Author

Braicu,Elena Ioana, Luketina,Hrvoje, Richter,Rolf, Cacsire Castillo-Tong,Dan, Lambrechts,Sandrina, Mahner,Sven, Concin,Nicole, Mentze,Monika, Zeillinger,Robert, Vergote,Ignace, Sehouli,Jalid, Braicu,Elena Ioana, Luketina,Hrvoje, Richter,Rolf, Cacsire Castillo-Tong,Dan, Lambrechts,Sandrina, Mahner,Sven, Concin,Nicole, Mentze,Monika, Zeillinger,Robert, Vergote,Ignace, and Sehouli,Jalid

Abstract

Elena Ioana Braicu,1 Hrvoje Luketina,1 Rolf Richter,1 Dan Cacsire Castillo-Tong,2 Sandrina Lambrechts,4 Sven Mahner,5 Nicole Concin,6 Monika Mentze,1 Robert Zeillinger,2,3 Ignace Vergote,4 Jalid Sehouli1 1Department of Gynecology, European Competence Center for Ovarian Cancer, Charité – Universitätsmedizin Berlin, Berlin, Germany; 2Department of Obstetrics and Gynecology, Comprehensive Cancer Center, Medical University of Vienna, 3Ludwig Boltzmann Cluster Translational Oncology, General Hospital of Vienna, Vienna, Austria; 4Department of Obstetrics and Gynecology, Universitaire Ziekenhuizen Leuven, Katholieke Universiteit Leuven, Leuven, Belgium; 5Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 6Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, AustriaPurpose: Hypoxia is a common phenomenon encountered in solid cancers, leading to chemotherapy resistance and therefore to aggressiveness of the disease. The homeostatic response to hypoxia is mediated by hypoxia-inducible factor-1 (HIF-1). The aim of this study was to investigate the impact of HIF1α in patients with primary epithelial ovarian cancer.Methods: In this multicentric study, 275 patients with advanced primary epithelial ovarian cancer were included. All patients underwent cytoreductive surgery with maximal surgical effort and adjuvant platinum-based chemotherapy. HIF1α expression was analyzed in tissue lysates, using an enzyme-linked immunosorbent assay.Results: HIF1α was detected in 79.3% of the tissue samples. Patients with increased HIF1α expression (cutoff: 80 pg/mg protein) in tumoral tissue lysates were more likely to have less favorable survival. HIF1α (P=0.009, hazard ratio [HR] 2.505, 95% confidence interval [95% CI] 1.252–5.013) together with International Federation of Gynecology and Obstetrics (III versus IV) (P

Published
2014

171. L1CAM in the Early Enteric and Urogenital System.

Author

Pechriggl, Elisabeth Judith, Concin, Nicole, Blumer, Michael J., Bitsche, Mario, Zwierzina, Marit, Dudas, Jozsef, Koziel, Katarzyna, Altevogt, Peter, Zeimet, Alain-Gustave, and Fritsch, Helga

Subjects
GENITOURINARY organs, CELL adhesion, EMBRYOLOGY, MEMBRANE proteins, GASTROINTESTINAL diseases
Abstract

L1 cell adhesion molecule (L1CAM) is a transmembrane molecule belonging to the L1 protein family. It has shown to be a key player in axonal guidance in the course of neuronal development. Furthermore, L1CAM is also crucial for the establishment of the enteric and urogenital organs and is aberrantly expressed in cancer originating in these organs. Carcinogenesis and embryogenesis follow a lot of similar molecular pathways, but unfortunately, comprehensive data on L1CAM expression and localization in human developing organs are lacking so far. In the present study we, therefore, examined the spatiotemporal distribution of L1CAM in the early human fetal period (weeks 8–12 of gestation) by means of immunohistochemistry and in situ hybridization (ISH). In the epithelia of the gastrointestinal organs, L1CAM localization cannot be observed in the examined stages most likely due to their advanced polarization and differentiation. Despite these results, our ISH data indicate weak L1CAM expression, but only in few epithelial cells. The genital tracts, however, are distinctly L1CAM positive throughout the entire fetal period. We, therefore, conclude that in embryogenesis L1CAM is crucial for further differentiation of epithelia. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

173. HIF1α is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer – a study of the OVCAD Consortium

Author

Braicu, Elena, primary, Hrvoje, Luketina, additional, Richter, Rolf, additional, Cacsire Castillo-Tong, Dan, additional, Lambrechts, Sandrina, additional, Mahner, Sven, additional, Concin, Nicole, additional, Mentze, Monika, additional, Zeillinger, Robert, additional, Vergote, Ignace, additional, and Sehouli, Jalid, additional

Published
2014
Full Text
View/download PDF

174. Erratum to “Quantitative levonorgestrel plasma level measurements in patients with regular and prolonged use of the levonorgestrel-releasing intrauterine system” [Contraception 86 (2012) 345–349]

Author

Seeber, Beata, primary, Ziehr, Stephanie C., additional, Gschlieβer, Andreas, additional, Moser, Christina, additional, Mattle, Verena, additional, Seger, Christoph, additional, Griesmacher, Andrea, additional, Concin, Nicole, additional, Concin, Hans, additional, and Wildt, Ludwig, additional

Published
2013
Full Text
View/download PDF

175. Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium

Author

Trillsch, Fabian, primary, Woelber, Linn, additional, Eulenburg, Christine, additional, Braicu, Ioana, additional, Lambrechts, Sandrina, additional, Chekerov, Radoslav, additional, van Nieuwenhuysen, Els, additional, Speiser, Paul, additional, Zeimet, Alain, additional, Castillo-Tong, Dan Cacsire, additional, Concin, Nicole, additional, Zeillinger, Robert, additional, Vergote, Ignace, additional, Mahner, Sven, additional, and Sehouli, Jalid, additional

Published
2013
Full Text
View/download PDF

177. A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer - a study of the OVCAD consortium

Author

Pils, Dietmar, primary, Tong, Dan, additional, Hager, Gudrun, additional, Obermayr, Eva, additional, Aust, Stefanie, additional, Heinze, Georg, additional, Kohl, Maria, additional, Schuster, Eva, additional, Wolf, Andrea, additional, Sehouli, Jalid, additional, Braicu, Ioana, additional, Vergote, Ignace, additional, Van Gorp, Toon, additional, Mahner, Sven, additional, Concin, Nicole, additional, Speiser, Paul, additional, and Zeillinger, Robert, additional

Published
2013
Full Text
View/download PDF

178. The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study.

Author

Nassir, Mani, Guan, Jun, Luketina, Hrvoje, Siepmann, Timo, Rohr, Irena, Richter, Rolf, Castillo-Tong, Dan, Zeillinger, Robert, Vergote, Ignace, Nieuwenhuysen, Els, Concin, Nicole, Marth, Christian, Hall, Christina, Mahner, Sven, Woelber, Linn, Sehouli, Jalid, and Braicu, Elena

Abstract

Patients with epithelial ovarian cancer (EOC) are at high risk of tumor recurrence. Human epididymis protein 4 (HE4) has been shown to be overexpressed in EOC. The primary aim of our study was to evaluate the role of HE4 in predicting recurrence in EOC patients. Furthermore, we assessed the role of HE4 in predicting recurrence after second-line chemotherapy. We retrospectively analyzed data of 92 out of 275 primary EOC patients of the multicenter project 'Ovarian Cancer: Diagnosis of a silent killer' (OVCAD). The concentrations of HE4 and CA125 were determined preoperatively and 6 months after the end of platinum-based first-line chemotherapy (FU) using ELISA and Luminex technique, respectively. The role of HE4 and CA125 for prediction of recurrence was determined using receiver operating characteristics (ROC) curves. Out of 92 patients included, 70 (76 %) were responders and 22 (23 %) non-responders in terms of response to platinum-based first-line chemotherapy. Median HE4 concentrations at follow-up (FU) differed between responders and non-responders (60.5 vs. 237.25 pM, p = 0.0001), respectively. The combined use of HE4 and CA125 at FU with cut-off values of 49.5 pM and 25 U/ml for HE4 and CA125, respectively, for predicting recurrence within 12 months after first-line chemotherapy performed better than HE4 or CA125 alone (area under the curve (AUC) 0.928, 95 % confidence intervals (CI) 0.838-1, p < 0.001). HE4 at FU could predict recurrence within 6 months after second-line chemotherapy (AUC 0.719, 95 % CI 0.553-0.885, p = 0.024). The combination of both elevated biomarkers revealed significantly worse estimated median progression-free survival (PFS; hazard ratio (HR) 8.14, 95 % CI 3.75-17.68, p < 0.001) and slightly worse PFS in those in whom only one biomarker was elevated (HR 1.46, 95 % CI 0.72-2.96, p = 0.292) compared to those patients in whom no biomarker was elevated. For the estimated median overall survival (OS), our analysis revealed similar results. HE4 in combination with CA125 performed better than CA125 and HE4 alone in predicting recurrence within 12 months after first-line chemotherapy. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

179. Quantitative levonorgestrel plasma level measurements in patients with regular and prolonged use of the levonorgestrel-releasing intrauterine system

Author

Seeber, Beata, primary, Ziehr, Stephanie C., additional, Gschlieβer, Aandrea, additional, Moser, Christina, additional, Mattle, Verena, additional, Seger, Christoph, additional, Griesmacher, Andrea, additional, Concin, Nicole, additional, Concin, Hans, additional, and Wildt, Ludwig, additional

Published
2012
Full Text
View/download PDF

182. Interval versus primary tumor debulking surgery in advanced ovarian cancer: Analysis of the European OVCAD data.

Author

Fotopoulou, Christina, primary, Braicu, Ioana, additional, Vergote, Ignace B., additional, Cadron, Isabelle, additional, Amant, Frederic, additional, Chekerov, Radoslav, additional, Castillo-Tong, Dan Cacsire, additional, Speiser, Paul, additional, Richter, Rolf, additional, Concin, Nicole, additional, Marth, Christian, additional, Mahner, Sven, additional, Trillsch, Fabian, additional, Zeillinger, Robert, additional, and Sehouli, Jalid, additional

Published
2012
Full Text
View/download PDF

183. The N-Terminally Truncated p53 Isoform Δ40p53 Influences Prognosis in Mucinous Ovarian Cancer

Author

Hofstetter, Gerda, primary, Berger, Astrid, additional, Berger, Regina, additional, Zorić, Arijana, additional, Braicu, Elena I., additional, Reimer, Daniel, additional, Fiegl, Heidi, additional, Marth, Christian, additional, Zeimet, Alain G., additional, Ulmer, Hanno, additional, Moll, Ute, additional, Zeillinger, Robert, additional, and Concin, Nicole, additional

Published
2012
Full Text
View/download PDF

184. Prognostic Value of Residual Tumor Size in Patients With Epithelial Ovarian Cancer FIGO Stages IIA–IV: Analysis of the OVCAD Data

Author

Polterauer, Stephan, primary, Vergote, Ignace, additional, Concin, Nicole, additional, Braicu, Ioana, additional, Chekerov, Radoslav, additional, Mahner, Sven, additional, Woelber, Linn, additional, Cadron, Isabelle, additional, Van Gorp, Toon, additional, Zeillinger, Robert, additional, Castillo-Tong, Dan Cacsire, additional, and Sehouli, Jalid, additional

Published
2012
Full Text
View/download PDF

185. Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells

Author

Kramer, Daniela, Stark, Nadine, Schulz-Heddergott, Ramona, Erytch, Norman, Edmunds, Shelley, Roßmann, Laura, Bastians, Holger, Concin, Nicole, Moll, Ute M, and Dobbelstein, Matthias

Abstract

All current regimens for treating ovarian cancer center around carboplatin as standard first line. The HSP90 inhibitor ganetespib is currently being assessed in advanced clinical oncology trials. Thus, we tested the combined effects of ganetespib and carboplatin on a panel of 15 human ovarian cancer lines. Strikingly, the two drugs strongly synergized in cytotoxicity in tumor cells lacking wild-type p53. Mechanistically, ganetespib and carboplatin in combination, but not individually, induced persistent DNA damage causing massive global chromosome fragmentation. Live-cell microscopy revealed chromosome fragmentation occurring to a dramatic degree when cells condensed their chromatin in preparation for mitosis, followed by cell death in mitosis or upon aberrant exit from mitosis. HSP90 inhibition caused the rapid decay of key components of the Fanconi anemia pathway required for repair of carboplatin-induced interstrand crosslinks (ICLs), as well as of cell cycle checkpoint mediators. Overexpressing FancA rescued the DNA damage induced by the drug combination, indicating that FancA is indeed a key client of Hsp90 that enables cancer cell survival in the presence of ICLs. Conversely, depletion of nuclease DNA2 prevented chromosomal fragmentation, pointing to an imbalance of defective repair in the face of uncontrolled nuclease activity as mechanistic basis for the observed premitotic DNA fragmentation. Importantly, the drug combination induced robust antitumor activity in xenograft models, again accompanied with depletion of FancA. In sum, our findings indicate that ganetespib strongly potentiates the antitumor efficacy of carboplatin by causing combined inhibition of DNA repair and cell cycle control mechanisms, thus triggering global chromosome disruption, aberrant mitosis and cell death.

Published
2017
Full Text
View/download PDF

187. Evidence for Cosmetics as a Source of Mineral Oil Contamination in Women

Author

Concin, Nicole, primary, Hofstetter, Gerda, additional, Plattner, Barbara, additional, Tomovski, Caroline, additional, Fiselier, Katell, additional, Gerritzen, Kerstin, additional, Semsroth, Severin, additional, Zeimet, Alain G., additional, Marth, Christian, additional, Siegl, Harald, additional, Rieger, Karl, additional, Ulmer, Hanno, additional, Concin, Hans, additional, and Grob, Koni, additional

Published
2011
Full Text
View/download PDF

188. Clinical Relevance of TAp73 and ΔNp73 Protein Expression in Ovarian Cancer

Author

Hofstetter, Gerda, primary, Berger, Astrid, additional, Chamson, Martina, additional, Müller-Holzner, Elisabeth, additional, Reimer, Daniel, additional, Ulmer, Hanno, additional, Uramoto, Hidetaka, additional, Marth, Christian, additional, G. Zeimet, Alain, additional, Zeillinger, Robert, additional, and Concin, Nicole, additional

Published
2011
Full Text
View/download PDF

191. E2F3a Is Critically Involved in Epidermal Growth Factor Receptor–Directed Proliferation in Ovarian Cancer

Author

Reimer, Daniel, primary, Hubalek, Michael, additional, Riedle, Svenja, additional, Skvortsov, Sergej, additional, Erdel, Martin, additional, Concin, Nicole, additional, Fiegl, Heidi, additional, Müller-Holzner, Elisabeth, additional, Marth, Christian, additional, Illmensee, Karl, additional, Altevogt, Peter, additional, and Zeimet, Alain G., additional

Published
2010
Full Text
View/download PDF

193. Plasma Fibrinogen Levels and Prognosis in Patients with Ovarian Cancer: A Multicenter Study

Author

Polterauer, Stephan, primary, Grimm, Christoph, additional, Seebacher, Veronika, additional, Concin, Nicole, additional, Marth, Christian, additional, Tomovski, Caroline, additional, Husslein, Heinrich, additional, Leipold, Heinz, additional, Hefler-Frischmuth, Katrin, additional, Tempfer, Clemens, additional, Reinthaller, Alexander, additional, and Hefler, Lukas, additional

Published
2009
Full Text
View/download PDF

194. Optimizing the dose of upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-directed dolaflexin antibody drug conjugate (ADC): A posthoc analysis of a phase 1b expansion study in ovarian cancer (319).

Author

Monk, Bradley, Concin, Nicole, Richardson, Debra, Ray-Coquard, Isabelle, Pothuri, Bhavana, Marth, Christian, Bernardo, Patricia, Burger, Robert, Im, Ellie, Aldairy, Wassim, Coleman, Robert, and Mirza, Mansoor

Subjects
*OVARIAN cancer, *OVARIAN epithelial cancer, *BODY surface area, *ADVERSE health care events
Abstract

Objectives: Effective and well-tolerated treatments for platinum- resistant ovarian cancer (PROC) remain a substantial unmet medical need. UpRi is a first-in-class Dolaflexin ADC targeting NaPi2b, a sodium-dependent phosphate transporter broadly expressed in high-grade serous epithelial ovarian cancer (OC), with limited expression in normal tissue. The purpose of this post-hoc analysis of data from the PhIb study is to determine if the dose of UpRi could be optimized in future studies to improve long-term tolerability and the therapeutic index. We evaluated the safety and overall response rate (ORR) in NaPi2b high and all evaluable patients (pts) based on various dose levels. Methods: The Ph1b PROC expansion cohort eligibility included pts with up to four prior lines of therapy. Pts were treated at either 36 or 43mg/m2 up to a maximum (max) dose of ~80mg for those patients with body surface area (BSA) ≥1.8m2, administered intravenously every four weeks. Tumor tissue was retrospectively evaluated for NaPi2b expression. An analysis was conducted on the expansion cohort to compare the efficacy and safety results of pts receiving doses ranging from 33-38mg/m2 (Group A, n =29) with those receiving >38mg/m2 (Group B, n =66). Group A included pts whose starting dose was 36mg/m2 (n =12) plus pts whose starting dose was ~80mg who received 33-38mg/m2 based on their BSA (n =17). Group B included pts in the 43mg/m2 group with BSA <1.8 (n =39) plus pts with BSA >1.8 but received >38mg/m2 (n =27). Two additional pts received <30mg/m2 and were not included in this analysis. Results: As of June 10, 2021, 97 pts were enrolled with a median age of 68 (33 to 87) years. The safety analysis included 95 pts: 29 in Group A and 66 in Group B. Dose reductions and discontinuations due to treatment-related adverse events (TRAEs) were lower in Group A (21% and 7%) than B (30% and 12%). Lower frequency of TRAEs was observed in Group A compared to B, 93% and 98%, respectively. The most common Grade >3 events included transient AST increase, fatigue, anemia, and thrombocytopenia; all were less frequent in Group A than B. No Grade 4 or 5 TRAEs were reported in Group A (See Table 1). Seventy-three pts were evaluable for response. The ORR was 36% (9/25) (95% CI: 18%-57%) in Group A and 23% (11/48) (95% CI: 12%-37%) in Group B. More responders were seen in high NaPi2b expressing tumors: ORR of 44% (7/16) (95% CI: 20%-70%) and 32% (7/22) (95% CI: 14%-55%) for Group A and B, respectively. Conclusions: In this post-hoc analysis of a phase Ib study comparing the safety and efficacy of UpRi in treating recurrent ovarian cancer, lower doses were associated with at least similar efficacy and improved tolerability than higher doses. These data support further clinical development of UpRi in the UPLIFT registrational study (NCT03319628), utilizing 36mg/m2 up to a max dose of approximately 80mg every four weeks. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

195. Response to: Correspondence on "ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors" by Thomassin-Nagarra et al.

Author

Timmerman, Dirk, Cibula, David, Planchamp, François, Bourne, Tom, Landolfo, Chiara, Testa, Antonia Carla, du Bois, Andreas, Chiva, Luis, Concin, Nicole, fisherova, Daniela, Froyman, Wouter, Lemley, Birthe, Loft, Annika, Mereu, Liliana, Morice, Philippe, Querleu, Denis, Vergote, Ignace, Vandecaveye, Vincent, Scambia, Giovanni, and Fotopoulou, Christina

Published
2021
Full Text
View/download PDF

197. Serum C-Reactive Protein as Independent Prognostic Variable in Patients with Ovarian Cancer

Author

Hefler, Lukas A., primary, Concin, Nicole, additional, Hofstetter, Gerda, additional, Marth, Christian, additional, Mustea, Alexander, additional, Sehouli, Jalid, additional, Zeillinger, Robert, additional, Leipold, Heinz, additional, Lass, Harald, additional, Grimm, Christoph, additional, Tempfer, Clemens B., additional, and Reinthaller, Alexander, additional

Published
2008
Full Text
View/download PDF

199. Vascular Endothelial Growth Factor Gene Polymorphisms Are Associated with Prognosis in Ovarian Cancer

Author

Hefler, Lukas A., primary, Mustea, Alexander, additional, Könsgen, Dominique, additional, Concin, Nicole, additional, Tanner, Berno, additional, Strick, Reiner, additional, Heinze, Georg, additional, Grimm, Christoph, additional, Schuster, Eva, additional, Tempfer, Clemens, additional, Reinthaller, Alexander, additional, and Zeillinger, Robert, additional

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results